Rodorubicin | CAS#96497-67-5 | tetraglycosidic anthracycline

MedKoo Cat#: 461395 | Name: Rodorubicin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rodorubicin is a new tetraglycosidic anthracycline with interesting preclinical antitumor activity.

Chemical Structure

Rodorubicin

CAS#96497-67-5

Theoretical Analysis

MedKoo Cat#: 461395

Name: Rodorubicin

CAS#: 96497-67-5

Chemical Formula: C48H64N2O17

Exact Mass: 940.4205

Molecular Weight: 941.03

Elemental Analysis: C, 61.27; H, 6.86; N, 2.98; O, 28.90

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Rodorubicin;

IUPAC/Chemical Name

(7R,8R,10S)-10-(((2R,4S,5S,6S)-5-(((2S,4aR,5aS,7S,9S,9aR,10aR)-2,9-dimethyl-3-oxooctahydro-2H,7H-dipyrano[2,3-b:4',3'-e][1,4]dioxin-7-yl)oxy)-4-(dimethylamino)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-7-(((2S,4S,5S,6S)-4-(dimethylamino)-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-8-ethyl-1,6,8,11-tetrahydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione

InChi Key

JXVAMODRWBNUSF-GVZAVIMWSA-N

InChi Code

InChI=1S/C48H64N2O17/c1-10-48(58)18-30(64-31-15-25(50(8)9)44(21(4)60-31)65-33-17-28-45(22(5)61-33)67-47-29(63-28)16-27(52)19(2)62-47)35-38(46(48)66-32-14-24(49(6)7)39(53)20(3)59-32)43(57)36-37(42(35)56)41(55)34-23(40(36)54)12-11-13-26(34)51/h11-13,19-22,24-25,28-33,39,44-47,51,53,56-58H,10,14-18H2,1-9H3/t19-,20-,21-,22-,24-,25-,28-,29+,30-,31-,32-,33-,39+,44+,45+,46+,47-,48+/m0/s1

SMILES Code

O=C1C2=C(O)C([C@@H](O[C@H]3C[C@H](N(C)C)[C@H](O)[C@H](C)O3)[C@@](O)(CC)C[C@@H]4O[C@H]5C[C@H](N(C)C)[C@H](O[C@H]6C[C@]7([H])O[C@@](CC([C@H](C)O8)=O)([H])[C@]8([H])O[C@]7([H])[C@H](C)O6)[C@H](C)O5)=C4C(O)=C2C(C9=C1C=CC=C9O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 941.03 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kraemer HP, Sedlacek HH. Rodorubicin, a new tetraglycosidic anthracycline. Behring Inst Mitt. 1988 Apr;(82):216-30. PubMed PMID: 3165634. 2: Verweij J, van der Burg ME, van Putten WL, Henzen-Logmans SC, Salewski E, Kraemer HP, Stoter G. Phase I studies of rodorubicin single bolus and daily times five, once every three weeks in patients with advanced solid tumors. Eur J Cancer Clin Oncol. 1989 Apr;25(4):627-32. PubMed PMID: 2714339. 3: Hermentin P, Doenges R, Gronski P, Bosslet K, Kraemer HP, Hoffmann D, Zilg H, Steinstraesser A, Schwarz A, Kuhlmann L, et al. Attachment of rhodosaminylanthracyclinone-type anthracyclines to the hinge region of monoclonal antibodies. Bioconjug Chem. 1990 Mar-Apr;1(2):100-7. PubMed PMID: 2095207. 4: Iwahashi T, Tone Y, Usui J, Watanabe H, Sugawara I, Mori S, Okazaki H. Selective killing of carcinoembryonic-antigen (CEA)-producing cells in vitro by the immunoconjugate cytorhodin-S and CEA-reactive cytorhodin-S antibody CA208. Cancer Immunol Immunother. 1989;30(4):239-46. PubMed PMID: 2598192. 5: Falkson G, Falkson HC, Alberts AS. Severe toxicity with cytorhodin S. Eur J Cancer. 1990 Jan;26(1):71-2. PubMed PMID: 2138484.